New and emerging agents in HER2-negative metastatic breast cancer: Implications for practice
emerging agents, including ADCs, for HER2-negative metastatic breast cancer and their impact on current and future practice. With insights from Prof. Giuseppe Curigliano, Prof. Hope Rugo and Prof. Peter Schmid. Watch now: https://touchoncologyime.org/new-and-... -------- This activity is funded by an independent medical education grant from Gilead Sciences, Inc. and is jointly provided by USF Health and touchIME.
▶︎
Updates in Systemic Therapy for Breast Cancer 2/8/23
▶︎
Medical update: HER2-Positive and triple-positive metastatic breast cancer
▶︎
Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD Strategies
▶︎
25 Brutal Truths a Breast Surgeon Learned about Breast Cancer
▶︎
Hot Topics Genomics in Primary Care Clinic - June 2026
▶︎
Stage 4 Breast Cancer - Part 3/4 - "Treatment of stage 4, HER2 positive breast cancers"
▶︎
Better Statistics CIC - Measuring the Economy - Morning Session
▶︎
My Targeted Therapy Experience - Ribociclib/Kisqali for Metastatic Breast Cancer
▶︎
HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
▶︎
3 Breast Cancer Trials That Will Change Care in 2026
▶︎
Depression Explained: Signs, Symptoms And Treatment With Dr Barakat
▶︎
Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer
▶︎
Breast Cancer: Ductal Carcinoma in Situ (DCIS) EXPLAINED
▶︎
What is HER2-Low Breast Cancer?
▶︎
How to treat HER2+ Breast Cancer in 2024 with Dr. Harold Burstein
▶︎
Should I Take an Aromatase Inhibitor? (5 Things Breast Cancer Survivors Are Not Told)
▶︎
Treatment Planning for Triple Negative Breast Cancer | 2022 Evolution Conference
▶︎
"This Food Can Repair DNA & Starve Cancer!" - What You NEED TO KNOW!
▶︎
Bone metastases in breast cancer: Screening, treatment and side effects
▶︎